

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CANbridge Pharmaceuticals Inc.**  
**北海康成製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1228)**

**POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON JUNE 27, 2024**

The Board hereby announces that all resolutions set out in the AGM Notice were duly passed by the Shareholders by way of a poll at the AGM held on Thursday, June 27, 2024.

**ANNUAL GENERAL MEETING (THE “AGM”)**

Reference is made to the circular (the “**AGM Circular**”) and the notice of the AGM (the “**AGM Notice**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) both dated June 6, 2024. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the AGM Circular.

**POLL RESULTS OF AGM**

The Board is pleased to announce that all of the proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the AGM held on Thursday, June 27, 2024. The poll results in respect of the resolutions passed at the AGM are as follows:

<b>ORDINARY RESOLUTIONS</b>		<b>NO. OF VOTES (APPROXIMATE %)*</b>	
		<b>For</b>	<b>Against</b>
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors of the Company (the “ <b>Directors</b> ”) and auditor of the Company for the year ended December 31, 2023.	165,339,150 (100.00%)	0 (0.00%)

ORDINARY RESOLUTIONS		NO. OF VOTES (APPROXIMATE %)*	
		For	Against
2.	(i) To re-elect Dr. James Qun Xue as an executive Director.	123,653,720 (100.00%)	0 (0.00%)
	(ii) To re-elect Dr. Kan Chen as a non-executive Director.	165,339,150 (100.00%)	0 (0.00%)
	(iii) To re-elect Mr. Peng Kuan Chan as an independent non-executive Director.	165,339,150 (100.00%)	0 (0.00%)
3.	To consider the re-appointment of Ernst & Young as the auditor of the Company for the year ending December 31, 2024 and to authorize the Board to fix its remuneration.	165,339,150 (100.00%)	0 (0.00%)
4.	To grant a general mandate to the Directors to issue new shares of the Company.	158,765,150 (96.02%)	6,574,000 (3.98%)
5.	To grant a general mandate to the Directors to repurchase shares of the Company.	165,339,150 (100.00%)	0 (0.00%)
6.	To extend the general mandate to issue new shares by adding the number of shares repurchased.	158,765,150 (96.02%)	6,574,000 (3.98%)
7.	To approve and adopt the amended Share Option Scheme and authorize the Directors to handle all matters in connection with the Share Option Scheme.	117,041,260 (94.68%)	6,574,000 (5.32%)
8.	To approve and adopt the amended RSU Scheme and authorize the Directors to handle all matters in connection with the RSU Scheme.	117,041,260 (94.68%)	6,574,000 (5.32%)

\* All percentages are rounded to two decimal places.

Please refer to the AGM Notice for the full text of the resolutions above.

As more than 50% were casted in favour of each of the above ordinary resolutions numbered 1 to 8, all of the above ordinary resolutions were duly passed as ordinary resolutions of the Company.

## GENERAL

As of the date of the AGM, a total of 424,838,320 Shares were in issue. Dr. James Qun Xue, being a Shareholder, and his associates (holding a total of 41,775,430 Shares on an aggregate basis) were required to abstain from voting on resolution numbered 2(i), Shareholders, who are holders of the outstanding Options, and their respective associates (holding a total of 42,113,890 Shares on an aggregate basis) were required to abstain from voting on resolution numbered 7, and Shareholders, who are holders of RSUs, and their respective associates (holding a total of 41,813,890 Shares on an aggregate basis) were required to abstain from voting on resolution No. 8. As such, the total number of Shares entitling the Shareholders to attend and vote for or against resolutions numbered 1 and 2(ii) to 6, 2(i), 7, and 8 were 424,838,320, 383,062,890, 382,724,430, and 383,024,430, respectively.

Save as disclosed above, (i) there were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (ii) no Shareholders were required to abstain from voting at the AGM under the Listing Rules; and (iii) no Shareholders have stated their intention in the AGM Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The Directors, namely Dr. James Qun Xue, Mr. Edward Hu, Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu, attended the AGM. Dr. Kan Chen did not attend the AGM due to other business arrangement.

By Order of the Board  
**CANbridge Pharmaceuticals Inc.**  
**Dr. James Qun Xue**  
*Chairman*

Hong Kong, June 27, 2024

*As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Dr. Kan Chen and Mr. Edward Hu as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.*